Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections
Microbial Biotechnology · 2023-07 · 16 (7) · 1456-1474
DOI: 10.1111/1751-7915.14268 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Biotechnology, online erschienen am 13.05.2023. Verfasst von Edward J A Douglas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Bath, Bath, UK. Hauptthemen laut MEDLINE: Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents, Drug Development, Staphylococcal Infections. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Medical Sciences.
Abstract (Originalsprache)
Antimicrobial resistance is a major obstacle for the treatment of infectious diseases and currently represents one of the most significant threats to global health. Staphylococcus aureus remains a formidable human pathogen with high mortality rates associated with severe systemic infections. S. aureus has become notorious as a multidrug resistant bacterium, which when combined with its extensive arsenal of virulence factors that exacerbate disease, culminates in an incredibly challenging pathogen to treat clinically. Compounding this major health issue is the lack of antibiotic discovery and development, with only two new classes of antibiotics approved for clinical use in the last 20 years. Combined efforts from the scientific community have reacted to the threat of dwindling treatment options to combat S. aureus disease in several innovative and exciting developments. This review describes current and future antimicrobial strategies aimed at treating staphylococcal colonization and/or disease, examining therapies that show significant promise at the preclinical development stage to approaches that are currently being investigated in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, University of Bath, Bath, UK.
ORCID-Profile: Edward J A Douglas, Maisem Laabei
Förderung
- Academy of Medical Sciences
Zitieren
APA
Douglas, E. J. A., Wulandari, S. W., Lovell, S. D., & Laabei, M. (2023). Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections. Microbial Biotechnology, 16(7), 1456-1474. https://doi.org/10.1111/1751-7915.14268
Vancouver
Douglas EJA, Wulandari SW, Lovell SD, Laabei M. Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections. Microbial Biotechnology. 2023;16(7):1456-1474. doi:10.1111/1751-7915.14268
BibTeX
@article{Douglas2023,
author = {Douglas, Edward J A and Wulandari, Sri W and Lovell, Scott D and Laabei, Maisem},
title = {Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections},
journal = {Microbial Biotechnology},
year = {2023},
volume = {16},
number = {7},
pages = {1456--1474},
doi = {10.1111/1751-7915.14268}
}
EUVIMED